Search bioRxiv⌕ Search

Biology subjects

Delbaje, E.

Publications and source records attributed to Delbaje, E..

3 recordsLinked to original sources

The self-sufficient Aspergillus fumigatus Δ9-fatty acid desaturase SdeA requires a fused cytochrome b5 domain and hinge-dependent self-association for virulence

Fungal {Delta}9-fatty acid desaturases are self-sufficient enzymes in which the electron-donating cytochrome b5 (Cytb5) module is fused to the catalytic core, yet whether this covalent linkage is architecturally required has remained untested. Here we show that in the human pathogen Aspergillus fumigatus the Cytb5 module of the {Delta}9-desaturase SdeA must act in cis, within a self-associated complex organized by a hinge segment. AlphaFold3 modeling predicts a dimer in which the Cytb5 domain of one protomer approaches the other's di-iron center at a distance compatible with electron tunneling, and reciprocal co-immunoprecipitation shows that full-length SdeA self-associates in vivo. The recombinant Cytb5 module displays the spectral signatures of a genuine heme-binding redox domain. Nevertheless, deleting the Cytb5 domain, substituting its heme-coordinating histidines, or removing the 25-residue hinge each abolishes growth and virulence in Galleria mellonella without disrupting endoplasmic reticulum targeting, and a detached Cytb5-containing segment does not restore function. Hinge deletion abolishes stable SdeA self-association, identifying this segment as a structural organizer of the catalytically competent complex. Finally, we find no evidence that the sdeB locus provides a backup {Delta}9-desaturase. These results define the architectural requirements of a self-sufficient fungal desaturase and identify vulnerabilities absent from the human {Delta}9-desaturase for antifungal targeting.

microbiology↗

Brilacidin, a novel antifungal agent against Cryptococcus neoformans

Cryptococcus neoformans causes cryptococcosis, one of the most prevalent fungal diseases, generally characterized by meningitis. There is a limited and not very effective number of drugs available to combat this disease. In this manuscript, we show the host defense peptide mimetic brilacidin (BRI) as a promising antifungal drug against C. neoformans. BRI is able to affect the organization of the cell membrane, increasing fungal cell permeability. We also investigated the effects of BRI against the model system Saccharomyces cerevisiae by analyzing libraries of mutants grown in the presence of BRI. In S. cerevisiae, BRI also affects the cell membrane organization, but in addition the cell wall integrity pathway and calcium metabolism. In vivo experiments show BRI significantly reduces C. neoformans survival inside macrophages and partially clears C. neoformans lung infection in an immunocompetent murine model of invasive pulmonary cryptococcosis. We also observed that BRI interacts with caspofungin (CAS) and amphotericin (AmB), potentiating their mechanism of action against C. neoformans. BRI+CAS affects endocytic movement, calcineurin, and mitogen activated protein kinases. Our results indicate that BRI is a novel antifungal drug against cryptococcosis. ImportanceInvasive fungal infections have a high mortality rate causing more deaths annually than tuberculosis or malaria. Cryptococcosis, one of the most prevalent fungal diseases, is generally characterized by meningitis and is mainly caused by two closely related species of basidiomycetous yeasts, Cryptococcus neoformans and Cryptococcus gattii. There are few therapeutic options for treating cryptococcosis and searching for new antifungal agents against this disease is very important. Here, we present brilacidin (BRI) as a potential antifungal agent against C. neoformans. BRI is a small molecule host defense peptide mimetic that has previously exhibited broad-spectrum immunomodulatory/anti-inflammatory activity against bacteria and viruses. BRI alone was shown to inhibit the growth of C. neoformans, acting as a fungicidal drug, but surprisingly also potentiated the activity of caspofungin (CAS) against this species. We investigated the mechanism of action of BRI and BRI+CAS against C. neoformans. We propose BRI as a new antifungal agent against cryptococcosis.

microbiology↗

Strain heterogeneity in a non-pathogenic fungus highlights factors contributing to virulence

Fungal pathogens exhibit extensive strain heterogeneity, including variation in virulence. Whether closely related non-pathogenic species also exhibit strain heterogeneity remains unknown. Here, we comprehensively characterized the pathogenic potentials (i.e., the ability to cause morbidity and mortality) of 16 diverse strains of Aspergillus fischeri, a non-pathogenic close relative of the major pathogen Aspergillus fumigatus. In vitro immune response assays and in vivo virulence assays using a mouse model of pulmonary aspergillosis showed that A. fischeri strains varied widely in their pathogenic potential. Furthermore, pangenome analyses suggest that A. fischeri genomic and phenotypic diversity is even greater. Genomic, transcriptomic, and metabolomic profiling identified several pathways and secondary metabolites associated with variation in virulence. Notably, strain virulence was associated with the simultaneous presence of the secondary metabolites hexadehydroastechrome and gliotoxin. We submit that examining the pathogenic potentials of non-pathogenic close relatives is key for understanding the origins of fungal pathogenicity.

evolutionary biology↗